Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25086325 | 0.81 | GRM5 (0.33) | GRM5CYP11B2CNR2 | |
| SCHEMBL7923008 | 0.77 | GRM5 (0.54) | GRM5APPCYP11B2MEN1KMT2A | |
| SCHEMBL26819633 | 0.76 | CYP11B2 (0.32) | CYP11B2 | |
| SCHEMBL927087 | 0.75 | GRM5 (0.53) | GRM5APPMEN1KMT2A | |
| SCHEMBL16519548 | 0.75 | GRM5 (0.53) | GRM5APPADRA2CCYP11B2MEN1 | |
| SCHEMBL10202528 | 0.73 | KDM4E (0.44) | MEN1KMT2A | |
| SCHEMBL11922134 | 0.72 | GRM5 (0.53) | GRM5CYP11B2 | |
| SCHEMBL12859573 | 0.70 | — | — | |
| SCHEMBL12859582 | 0.70 | DRD4 (0.32) | — | |
| SCHEMBL11922155 | 0.70 | KDM4E (0.36) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| US-9546165-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GRM5 3566/4885APP 4000/4885ADRA2A 4602/4885 |
| US-20230130909-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, HK1 | GRM5 4188/4885APP 1641/4885ADRA2A 4346/4885 |
| US-20190119268-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | GRM5 3566/4885APP 4000/4885ADRA2A 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.